When Does Ibrance Patent Expiry Occur?
The earliest anticipated patent expiry for Ibrance (palbociclib) is in 2027 [1]. This date is based on the expiration of certain compound patents.
What Other Patents Protect Ibrance?
Beyond the initial compound patents, Ibrance is protected by multiple other patents, including those related to its formulation and method of use [1]. These additional patents could extend market exclusivity further. For a comprehensive overview of Ibrance's patent landscape, DrugPatentWatch.com offers detailed information [1].
Can Generic Versions of Ibrance Enter the Market Before Patent Expiry?
The entry of generic versions of Ibrance before the expiry of all relevant patents is unlikely unless those patents are successfully challenged in court. Companies often rely on a portfolio of patents to maintain market exclusivity for extended periods [1].
How Does Ibrance Work?
Ibrance is a targeted therapy that works by inhibiting cyclin-dependent kinases (CDKs) 4 and 6 [2]. These enzymes play a role in cell division, and their inhibition can slow or stop the growth of cancer cells that rely on these pathways for proliferation [2].
Who Makes Ibrance?
Ibrance is manufactured and marketed by Pfizer [3].
What are the Treatment Indications for Ibrance?
Ibrance is approved for the treatment of certain types of advanced or metastatic breast cancer [2]. It is typically used in combination with an aromatase inhibitor or fulvestrant for postmenopausal women and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, following prior endocrine therapy [2]. It is also indicated for similar patients whose disease has progressed after prior endocrine therapy [2].
What Clinical Data Supports Ibrance's Efficacy?
Clinical trials have demonstrated that Ibrance, in combination with endocrine therapy, significantly improves progression-free survival in patients with HR-positive, HER2-negative advanced or metastatic breast cancer compared to endocrine therapy alone [2].
What are the Risks Associated with Ibrance Treatment?
Common side effects of Ibrance include neutropenia (low white blood cell count), fatigue, nausea, diarrhea, vomiting, hair loss, and stomatitis (inflammation of the mouth) [2]. More serious side effects can include severe neutropenia, which can lead to infections [2]. Patients are closely monitored by their healthcare providers during treatment [2].
What is the Cost of Ibrance?
The cost of Ibrance can be substantial, as is common with many targeted cancer therapies. Patient assistance programs are often available to help offset the financial burden [4].
What are the Alternatives to Ibrance?
Treatment options for HR-positive, HER2-negative advanced or metastatic breast cancer include other CDK4/6 inhibitors, such as abemaciclib and ribociclib, as well as various endocrine therapies and chemotherapy regimens [2][5]. The choice of treatment depends on individual patient factors and disease characteristics.
---
Sources:
[1] https://drugpatentwatch.com/drug/ibrance
[2] https://www.ibrance.com/
[3] https://www.pfizer.com/
[4] https://www.ibrance.com/patients/patient-support
[5] https://www.cancer.gov/types/breast/advanced-treatment